E23.1
Drug-induced hypopituitarism
E23.1 (also written E231) is a billable ICD-10-CM diagnosis code for drug-induced hypopituitarism. It is part of the FY2027 code set, effective October 1, 2026. It is one of the 6 codes in category E23 (Hypofunction and other disorders of the pituitary gland). The Alphabetic Index lists it under 2 entries. Its coding notes include a Use additional code instruction and 5 Excludes1 entries.
Use additional code
Add the listed code as a secondary code, if known.
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Excludes1
Not coded here. The listed conditions generally should not be reported together.
Care settings
How CMS programs treat this code. These are CMS claim edits and list entries, not coverage or eligibility rules.
Home Health Primary
Accepted as the primary (principal) diagnosis on a home health claim. The Home Health Grouper assigns it to the MMTA - Endocrine clinical group.
Source: CMS Home Health Grouper Software v07.2.26, effective October 1, 2026Includes
Further defines or gives examples of the content of the category.
- the listed conditions whether the disorder is in the pituitary or the hypothalamus
Notes
Also from chapter/block level (1 note)
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Alphabetic Index terms
Terms the official Alphabetic Index lists for this code. 2 entries